The primary objective of this study was to determine the efficacy and dose-effect relation of the new oral phosphate binder Lenziaren® in healthy cats fed with a standard diet (containing ~0.2% phosphorus).
Another reason possibly obscuring a potential difference of TSPO binding between patients with MS and healthy controls is the 'non-binder' issue for TSPO imaging.
In contrast, absorption of iron from the iron-based phosphate binder PA21 was higher in healthy human subjects compared to patients undergoing dialysis [ 19].
Significant reductions in serum phosphate concentrations by Lenziaren®, as one would expect for a phosphate binder, were reported in previous studies in healthy cats fed a renal diet for 28 days [ 15] and in cats with CKD [ 17].
In a PET study with healthy human subjects, Fujita et al. reported the existence of non-binders for [C]PBR28, whereas no such phenomenon has been described for [C]PK11195 [ 49].
An oral phosphate binder would be expected to decrease serum phosphate concentrations, however homeostatic mechanisms in healthy cats could have maintained serum concentrations during the relatively short duration (30 days) of administration of Lenaziaren®.
The efficacy, acceptability and tolerability of the new oral phosphate binder Lenziaren® (SBR759) were evaluated in a randomized parallel-group design study in 36 healthy cats (n = 6 per group).
She paged through a huge binder of sperm donors at the California Cryobank and quickly made her choice: He was healthy, tall, athletic, and creative.
Tolerability and efficacy of the intestinal phosphate binder Lantharenol® (lanthanum carbonate octahydrate) were tested in two prospective, randomized and negative controlled laboratory studies with healthy adult cats fed commercial maintenance diets non-restricted in phosphorus.
